Entropy Neurodynamics Limited has released a press release.
First patient enrolled in Binge Eating Disorder Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- Appendix 4E and 2025 Annual Report
- Landmark EEG Biomarker Agreement for Precision Psychiatry
- $2.6m in non-dilutive capital funding secured
- Patient recruitment for world first TRP-8803 trial underway
- Binge Eating Disorder Trial receives Human Ethics approval
Later from Entropy Neurodynamics
- Trading Halt
- $6.1m in new funding to accelerate clinical development
- BED trial accelerates - enrolment grows, dosing in two weeks
- First patient successfully dosed in TRP 8803 BED trial
- First BED patient completes second TRP-8803 infusion
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics